Generated by AI
Evotec SE Sponsored ADR is a healthcare and life sciences depositary receipt representing Evotec SE, a drug discovery and development company headquartered in Hamburg, Germany. The company supports pharmaceutical and biotechnology partners with integrated research services across early-stage drug discovery, including target identification, screening, lead optimization, pharmacology, structural biology, and bioanalytics. Its work is organized around discovery and development platforms that help clients advance small molecules and biologics through preclinical research. Evotec SE also operates collaborative research programs and technology-enabled solutions that serve a broad range of therapeutic areas. As a Sponsored ADR, the asset provides U.S. investors with exposure to Evotec SE’s business in a U.S.-traded format while reflecting the company’s role in the global outsourced drug discovery market.
WebsiteEssener Bogen 7
Hamburg, 22419
Germany
The latest articles about EVO.
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026. The conference call will be held in English.
Summary of Oct 23's posts. Generated by AI.
Summary of Dec 8's posts. Generated by AI.
Summary of Jul 21's posts. Generated by AI.
Summary of Jul 17's posts. Generated by AI.
Investors talking about EVO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.